We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Omalizumab on Responses to Cat Allergen Challenge

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00604786
First Posted: January 30, 2008
Last Update Posted: May 10, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
Johns Hopkins University
  Purpose
This research is being done to study the effects of the drug omalizumab (Xolair) in people with cat allergies. The investigators will use omalizumab to study changes in the cells in the nose, skin and blood that cause allergies. The investigators predict that cells in the blood will be effected before cells in the nose or skin.

Condition Intervention
Allergic Rhinitis Drug: omalizumab Drug: placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: Pilot Study of the Effect of Omalizumab on Basophil and Mast Responses to Intranasal Cat Allergen Challenge

Resource links provided by NLM:


Further study details as provided by Johns Hopkins University:

Primary Outcome Measures:
  • Change in Basophil Surface IgE [ Time Frame: Change from baseline to 3.5 months ]

    Flow cytometry in mean fluorescence units.

    100%*[(3.5 month value minus baseline value)/baseline value]



Enrollment: 18
Study Start Date: July 2007
Study Completion Date: January 2009
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Omalizumab subcutaneous

This active are will receive treatment with omalizumab subcutaneously at the dose currently FDA-approved for the treatment of allergic asthma. There is a weight and IgE based dosing table in the and subjects receive therapy by subcutaneous injection every 2 or 4 weeks. The lower range of dosing is 150 mg q 4weeks ( one injection) with the upper range 375 mg every 2 weeks ( three injections).

The dosing is based on IgE levels and IGE and is given by subcutaneous injection every 2 to 4 weeks

Drug: omalizumab
Dosing is based on IgE level and weight given every 2 or 4 weeks
Other Name: Xolair
Placebo Comparator: Placebo Subcutaneous

This placebo arm will receive identical treatment with placebo injections subcutaneously at the dose currently FDA-approved for the treatment of allergic asthma. There is a weight and IgE based dosing table in the and subjects receive therapy by subcutaneous injection every 2 or 4 weeks. The lower range of dosing is 150 mg q 4weeks ( one injection) with the upper range 375 mg every 2 weeks ( three injections).

The dosing is based on IgE levels and IGE and is given by subcutaneous injection every 2 to 4 weeks.

Drug: placebo
Dosing is based on IgE level and weight given every 2 or 4 weeks

Detailed Description:
Omalizumab is a monoclonal antibody directed against Immunoglobulin E (IgE) and is FDA-approved for use in allergic asthma, though its clinical role is not precisely defined. It binds IgE on the same site of the Fc domain as the high affinity IgE receptor (FcεRI), and therefore, blocks the interaction between IgE and mast cells or basophils. It, therefore, may be used as a mechanistic tool in the study of IgE. As IgE levels are reduced with omalizumab, FcεRI expression on human basophils is reduced. This reduction of basophil receptors and allergen induced activation is pronounced within 7 days of the initial administration and is reversible once omalizumab administration is discontinued. The omalizumab-induced reductions in mast cell FcεRI expression and function is unchanged at day 7 and significantly reduced by day 70. These changes were based upon intravenously administered omalizumab at a dose of 0.03 mg/kg/IU IgE/mL in a total of three subjects. We propose to exploit the kinetics of faster omalizumab effects on circulating basophils relative to tissue mast cells to elucidate the role of the basophil versus mast cell activation in nasal airway allergen challenge, which has not been studied to date.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ability to understand and provide informed consent
  • Male or Female (non-pregnant), age 18-50
  • Females must be: Surgically sterile (hysterectomy, bilateral oophorectomy, bilateral tubal ligation), OR postmenopausal (at least 1 year since last menses), OR using a medically acceptable form of birth control throughout the duration of the study.
  • Clinical history of seasonal or perennial allergic rhinitis for at least two years, with or without mild persistent asthma
  • Positive puncture skin test greater than or equal to 5 mm diluent control
  • Positive Immunocap to Fel d 1 > 0.35 kallikrein unit/L
  • Positive intranasal cat allergen challenge as defined by > 5 sneezes or a tripling of measured nasal lavage mediators
  • In vitro assay of basophil responsiveness to cat allergen with greater than 20% histamine release
  • The use of antihistamines, cromolyn, leukotriene modifiers and other non-steroid (astelin and topical decongestants), nasal medications will be allowed, but they will be withheld for 5 days prior to each nasal allergen provocation session. Inhaled corticosteroids for mild asthma will be permissible.
  • No known contraindications to therapy with omalizumab

Exclusion Criteria:

  • Asthma with forced expiratory volume at one second (FEV1) < 80%, moderate to severe asthma classification per National Asthma Education and Prevention Program Expert Panel (NAEP) Standards (1997 National Asthma Education and Prevention Program Expert Panel Report II guidelines)
  • Serum IgE levels less than 30 IU/mL or greater than 700 IU/mL at the time of enrollment will be excluded
  • Unexplained elevation of erythrocyte sedimentation rate (ESR), hematocrit < 32%, white blood cell (WBC) count 2400/microliter lower limit of normal, platelet < 75000/microliter, creatinine > 141.4 micromolar/L, or aspartate aminotransferase (AST) > 100 IU/L
  • Body weight less than 30 kg or greater than 150 kg will be excluded.
  • Plans to become pregnant or breastfeed will be excluded from the study
  • A perforated nasal septum, structural nasal defect, large nasal polyps causing obstruction, evidence of acute or chronic sinusitis
  • A life expectancy less than 6 months
  • A terminal illness as determined by the investigator
  • A history of malignancy, anaphylaxis or bleeding disorder are also exclusion illnesses.
  • Mental illness or history of drug or alcohol abuse that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements.
  • Inability or unwillingness of a participant to give written informed consent or comply with study protocol
  • Use of any investigational drugs within 8 weeks of participation
  • Contraindications to omalizumab include patients with a previous hypersensitivity to omalizumab
  • Recent recipient of any licensed or investigational live attenuated vaccine(s) within two months of study initiation such as flu mist.
  • Prior use of omalizumab
  • Frequent sinusitis (>2/ documented episodes per year) or active sinusitis within 2 weeks of enrollment
  • Use of immunotherapy within the last 5 years
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00604786


Locations
United States, Maryland
Johns Hopkins Asthma and Allergy Center
Baltimore, Maryland, United States, 21224
Sponsors and Collaborators
Johns Hopkins University
National Institute of Allergy and Infectious Diseases (NIAID)
Investigators
Principal Investigator: Sarbjit S Saini, M.D. Johns Hopkins University
  More Information

Additional Information:
Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Johns Hopkins University
ClinicalTrials.gov Identifier: NCT00604786     History of Changes
Other Study ID Numbers: NA_00007520
U19AI070345 ( U.S. NIH Grant/Contract )
First Submitted: January 4, 2008
First Posted: January 30, 2008
Results First Submitted: December 4, 2013
Results First Posted: April 4, 2017
Last Update Posted: May 10, 2017
Last Verified: April 2017

Keywords provided by Johns Hopkins University:
Basophils
Mast Cells
IgE
IgE receptors
omalizumab

Additional relevant MeSH terms:
Rhinitis
Rhinitis, Allergic
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Omalizumab
Anti-Allergic Agents
Anti-Asthmatic Agents
Respiratory System Agents